The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1567
ISSUE 1567
March 11, 2019
Xyosted - A Testosterone Auto-Injector for Hypogonadism
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
March 11, 2019 (Issue: 1567)
The FDA has approved an auto-injector formulation of
testosterone enanthate (Xyosted – Antares Pharma) for
once-weekly subcutaneous self-administration in adult
males with conditions associated with a deficiency or
absence of endogenous testosterone. It is the first subcutaneous
formulation of testosterone to be approved by
the FDA. Xyosted is contraindicated for treatment of low
testosterone levels associated with aging.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Xyosted - A Testosterone Auto-Injector for Hypogonadism
Article code: 1567b
Electronic, downloadable article - $45
Article code: 1567b
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
